KPTI News and Press, Karyopharm Therapeutics Inc. From 05/16/19

-- Oral Presentation Highlighting Updated Data from the Phase 1b/2 STOMP Study Arm Evaluating Selinexor and Dexamethasone in Combination with Darzalex® in Patients with Relapsed or Refractory Multiple Myeloma -- -- Two Posters Highlighting Updated Data from the STOMP Arms Evaluat...

Karyopharm Therapeutics Inc. (KPTI) Q1 2019 Results Conference Call May 09, 2019 08:30 AM ET Company Participants Ian Karp - VP, IR and Public Relations Dr. Michael Kauffman - CEO Mike Mason - CFO Anand Varadan - Chief Commercial Officer Conference Call Participants Brian...

Karyopharm Therapeutics (NASDAQ: KPTI ): Q1 GAAP EPS of -$1.09 misses by $0.23 . More news on: Karyopharm Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

--  FDA Extends Review Period for Selinexor New Drug Application to July 6, 2019 -- -- Selinexor MAA Validated in Europe; Approval Decision Expected by End of 2019 -- -- Conference Call Scheduled for Today at 8:30 a.m. ET -- NEWTON, Mass., May 09,...

NEWTON, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that the Company’s management team will participate in the following upcoming investor conferences:  The Bank of America Merri...

-- Conference Call Scheduled for Thursday, May 9, 2019 at 8:30 a.m. ET -- NEWTON, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2019 financial results on Thursd...

Achieve Life Sciences (NASDAQ: ACHV ) +77%  on advancement of cytisinicline. More news on: Achieve Life Sciences, Inc., Soleno Therapeutics, Inc., MDC Partners Inc., Stocks on the move, Read more ...

Karyopharm Therapeutics (NASDAQ: KPTI ) is up  17%  premarket on light volume in response to its announcement that the FDA has extended the review period 90 days for its marketing application seeing approval for selinexor, combined with dexamethasone, for the treatment of patient...

NEWTON, Mass. , March 14, 2019 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug A...

Karyopharm Therapeutics Inc. (KPTI) Q4 2018 Earnings Conference Call February 28, 2019 8:30 AM ET Company Participants Ian Karp - Vice President, Investor and Public Relations Michael Kauffman - Chief Executive Officer Mike Mason - Chief Financial Officer Jatin Shah - Senior Vi...